Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Apo-Escitalopram · DIN 02295016 Manufacturer: Apotex Inc.; listing date 2014-11-27 Health Canada: Marketed since 2014-09-10 · brand APO-ESCITALOPRAM · ATC N06AB10 ESCITALOPRAM · form Tablet · route Oral · ingredients ESCITALOPRAM (ESCITALOPRAM OXALATE) 10 MG · company Apotex inc · schedule Prescription

DIN 02295016: Apo-Escitalopram Raw flags: sec3=Y Item: 281604118; group id 460; item number 1152; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.3109; ministry $0.3109 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02295016 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78034

Interchangeable products

Ach-Escitalopram · DIN 02434652 · $0.3109 Auro-Escitalopram · DIN 02397358 · $0.3109 Cipralex · DIN 02263238 · $0.3109 Escitalopram · DIN 02429039 · $0.3109 Escitalopram · DIN 02430118 · $0.3109 Jamp Escitalopram · DIN 02508893 · $0.3109 Jamp-Escitalopram · DIN 02429780 · $0.3109 M-Escitalopram · DIN 02471418 · $0.3109 Mar-Escitalopram · DIN 02423480 · $0.3109 Mint-Escitalopram · DIN 02407418 · $0.3109 Mylan-Escitalopram · DIN 02309467 · $0.3109 NRA-Escitalopram · DIN 02476851 · $0.3109 Natco-Escitalopram · DIN 02554909 · $0.3109 PMS-Escitalopram · DIN 02469243 · $0.3109 Ran-Escitalopram · DIN 02385481 · $0.3109 Sandoz Escitalopram · DIN 02364077 · $0.3109 Teva-Escitalopram · DIN 02318180 · $0.3109

Shortage status: resolved shortage (ended 2024-09-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02295016

Shortage record checked 2026-09-13T08:10:21.292534+00:00